# Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer

> **NCT00766142** · PHASE2 · TERMINATED · sponsor: **Institut Bergonié** · enrollment: 18 (actual)

## Conditions studied

- Colorectal Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** fluorouracil
- **DRUG:** leucovorin calcium
- **DRUG:** oxaliplatin
- **PROCEDURE:** adjuvant therapy
- **PROCEDURE:** therapeutic conventional surgery

## Key facts

- **NCT ID:** NCT00766142
- **Lead sponsor:** Institut Bergonié
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05-01
- **Primary completion:** 2013-09-17
- **Final completion:** 2013-09-17
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** In 2008, new data highlighted that Cetuximab had no efficacy in case of KRAS mutation. As such, eligibility criteria were revised and limited to KRAS wild-type. Inclusions were thus slown down considerably, and the trial was stopped.
- **Last updated:** 2025-08-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00766142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00766142, "Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00766142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*